Routine

Benign prostatic hyperplasia (BPH) / male lower urinary tract symptoms (LUTS)

Benign prostatic hyperplasia · Genitourinary
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Non-malignant prostatic enlargement causing bladder outlet obstruction and storage/voiding LUTS (hesitancy, weak stream, incomplete emptying, frequency, nocturia, urgency) in older men. Common and progressive; complications include acute urinary retention, recurrent UTI, bladder stones, haematuria and obstructive uropathy/renal impairment. Management is symptom- and risk-based: conservative measures, alpha-blockers for rapid symptom relief, 5-alpha-reductase inhibitors to shrink large glands and modify progression, combination therapy for enlarged prostates, and surgery (TURP) for refractory/complicated disease. (Acute urinary retention is managed separately.)

Red flags

  • Acute urinary retention (painful palpable bladder) or high-pressure chronic retention with renal impairment/hydronephrosis — catheterise/decompress
  • Haematuria (visible or persistent microscopic) — exclude bladder/renal malignancy
  • Hard/nodular prostate or rising PSA — exclude prostate cancer
  • Recurrent UTI or bladder stones from incomplete emptying
  • Neurological symptoms (saddle anaesthesia, leg weakness) suggesting cauda equina rather than BPH

Assessment

Differential diagnosis

  • Prostate cancer (hard/nodular prostate, raised/rising PSA)
  • Overactive bladder / detrusor overactivity
  • Urethral stricture
  • UTI / chronic prostatitis
  • Bladder cancer (haematuria, irritative symptoms)
  • Neurogenic bladder (diabetes, spinal pathology); polyuria (diabetes, diuretics)

Investigations

  • Symptom quantification: IPSS score + quality-of-life question; bladder/voiding diary (nocturnal polyuria)
  • Urinalysis (infection, haematuria, glucose); U&E/creatinine (exclude obstructive renal impairment)
  • PSA (after counselling) — correlates with prostate volume and progression risk; interpret for cancer risk
  • Digital rectal examination (size, consistency, nodules)
  • Post-void residual volume (bladder scan) and urinary flow rate (uroflowmetry) where available
  • Renal tract ultrasound if renal impairment, high residual, haematuria or recurrent infection

Management

  • Exclude/treat complications first: significant retention, obstructive renal impairment, recurrent UTI, bladder stones or suspected cancer -> appropriate referral/management
  • Mild symptoms (IPSS <8) or minimal bother: watchful waiting + lifestyle advice (fluid timing, reduce evening caffeine/alcohol, bladder training, treat constipation, review diuretics/anticholinergics)
  • Bothersome moderate-severe voiding symptoms: start an alpha-1 blocker for rapid symptom relief (effect within days)
  • If prostate is enlarged (volume >30-40 mL or PSA >1.4-1.5 ng/mL) and progression risk high: add/choose a 5-alpha-reductase inhibitor (slow effect over 6-12 months; reduces retention/surgery risk)
  • Combination alpha-blocker + 5-ARI for men with enlarged prostate and significant symptoms (MTOPS/CombAT: greater reduction in progression, retention and surgery than monotherapy)
  • Consider an antimuscarinic or beta-3 agonist add-on for predominant storage/overactive symptoms once significant residual/obstruction excluded; a PDE5 inhibitor (tadalafil) if coexisting erectile dysfunction
  • Refer to urology for refractory symptoms, recurrent retention/UTI, stones, renal impairment, bothersome haematuria or diagnostic uncertainty -> surgical options (TURP, laser, prostatic urethral lift, etc.)

Drugs & doses

Tamsulosin 400 micrograms PO once daily (alpha-1 blocker; fast symptom relief) [verify local dose]
Alfuzosin 10 mg PO once daily OR doxazosin 1-8 mg PO once daily (alternative alpha-blockers; watch postural hypotension) [verify local dose]
Finasteride 5 mg PO once daily (5-ARI; shrinks gland, reduces progression/retention over 6-12 months; lowers PSA ~50%) [verify local dose]
Dutasteride 500 micrograms PO once daily (dual 5-ARI; used in CombAT combination) [verify local dose]
Combination dutasteride 500 micrograms + tamsulosin 400 micrograms PO once daily for enlarged prostate with significant symptoms [verify local dose]
Tadalafil 5 mg PO once daily (LUTS with erectile dysfunction) [verify local dose]
Antimuscarinic (e.g. solifenacin) or mirabegron for persistent storage symptoms once obstruction/high residual excluded [verify local dose]

Disposition

Primary-care managed with lifestyle measures and medical therapy; routine urology referral for refractory/bothersome symptoms, complications, diagnostic uncertainty or suspected malignancy. Acute retention and obstructive renal impairment need urgent decompression (see acute urinary retention).

Complications & pitfalls

  • Acute and chronic urinary retention
  • Obstructive uropathy -> post-renal AKI/CKD (high-pressure chronic retention)
  • Recurrent UTI, bladder calculi, bladder decompensation/diverticula
  • Haematuria
  • Post-TURP syndrome and sexual side effects of therapy (5-ARI: reduced libido/ejaculatory changes; alpha-blocker: retrograde ejaculation, hypotension, intraoperative floppy iris syndrome)

Exam pearls

  • Alpha-blockers relieve symptoms fast but do NOT alter disease progression; 5-ARIs shrink the gland and reduce retention/surgery but take months — combine them for men with genuinely enlarged prostates (MTOPS, CombAT).
  • 5-ARIs halve PSA — DOUBLE the measured PSA after ~6 months on treatment when assessing cancer risk, and investigate any rise on therapy.
  • Warn men on tamsulosin/alpha-blockers about intraoperative floppy iris syndrome before cataract surgery, and about postural hypotension (especially doxazosin).
  • Nocturnal polyuria (from a voiding diary) is often the real driver of nocturia and is not fixed by prostate drugs — address fluid timing and medical causes.
  • Always exclude the serious mimics: nodular prostate/rising PSA (cancer) and visible haematuria (urothelial cancer).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.